Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GSK plc (GSK) vs Progressive Corp (PGR) Price & Performance

Progressive CorpTrade

Price performance (Past 24H)

Key statistics

GSK plc vs Progressive Corp — how do they compare? GSK plc trades at $50.4 (market cap $102.60B), while Progressive Corp trades at $209.54 (market cap $123.45B). The key difference: Progressive Corp is the larger of the two by market cap, and Progressive Corp pays the higher dividend (6.55%). Which is the better fit depends on your goals.

GSKPGR
Market Cap
$102.60B$123.45B
Sector
HealthFinancials
52-Week High
$61.18$252.68
52-Week Low
$38.22$190.40
Enterprise Value
$123.04B$131.66B
Dividend Yield
3.57%6.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.

Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.

Progressive Corp

Progressive (PGR) trades at $213.95, down 0.64% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamental performance with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income reaching $11.3B. Recent Q2 2026 earnings beat expectations at $4.85 per share, though the combined ratio widened to 87.1%, indicating potential growth trade-offs. Analyst consensus price target stands at $231.20 with 37% buy ratings.

PGR presents a compelling investment case with reasonable valuation (P/E 10.65) and strong profitability (ROE 34.94%), though investors face risks from competitive pressures and potential margin compression as the company expands its bundled insurance offerings. The stock offers 8% upside to consensus target with balanced risk-reward profile.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK

About Progressive Corp

Progressive underwrites private and commercial auto insurance and specialty lines

Read more on PGR